Lucid Diagnostics Finally Secures a Commercial Coverage Landmark — Will Medicare Follow?

A Pivotal First Step in Commercial Reimbursement

Lucid Diagnostics (LUCD) has spent the past year treading water — maintaining ~2,500–3,000 EsoGuard tests per quarter while awaiting a Medicare draft LCD that seems perpetually just around the corner. But the Q2 2026 update revealed a genuine inflection point: the company secured its first commercial coverage policy through Concert, a laboratory benefit manager (LBM). This isn't a pilot or a one-off contract; it's an independent third-party assessment that places EsoGuard squarely within medically necessary care, and it has already translated into coverage for multiple client health plans.

As CEO Lishan Aklog explained in the prepared remarks, “this is a major commercial coverage milestone and represents third-party review of EsoGuard’s clinical evidence” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-08-13. Concert went further, concluding that the test is medically necessary and that the evidence demonstrates improved health outcomes, while noting that competing esophageal precancer tests were deemed investigational due to insufficient evidence.

The near-term impact is meaningful: three of Concert’s client plans have already adopted the policy, and management expects several more in coming quarters. With just under 10 million covered lives under Concert’s umbrella, this gives Lucid a defined beachhead in specific geographies — primarily the Midwest and upper Midwest — where the company can concentrate its sales and contracting efforts. “It gives us the opportunity to allocate resources in a geographic fashion consistent with that” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-08-13, Aklog noted in the Q&A. This was the culmination of a strategy telegraphed months earlier; on the prior call, management acknowledged “getting the first one through the door has had a very significant effect in our ongoing conversations” — Lishan Aklog, Chairman and CEO · 2025-08-13 and hinted at a broader pipeline: “we have a pretty significant pipeline” — Lishan Aklog, Chairman and CEO · 2025-08-13.

The MVAC Pivot and the VA Tailwind

Management is also rebalancing the commercial engine around what CFO Dennis McGrath calls MVAC — Medicare, VA, and contracted revenue. In the second quarter, just under 40% of tests fell into that category, up substantially from the prior quarter, and the shift is visible in improved revenue conversion. McGrath detailed the new incentive structure: “our comp plans are now more heavily weighted towards what the team’s calling MVAC, Medicare, VA, and contracted revenue” — Dennis McGrath, Chief Financial Officer · 2026-08-13. This is a deliberate attempt to grow revenue even as total test volume stays flat, and it’s already working — recognized revenue rose 17% sequentially despite flat volume.

The Veterans Affairs channel remains a longer-duration play. The company has built a robust pipeline of VA centers and is “getting essentially no pushback from clinicians,” but purchase orders and volume are expected to materialize mainly in the new federal fiscal year beginning October 1. The VA’s 9 million covered lives, at the Medicare rate of roughly $1,938 per test, represent a substantial addressable opportunity that Lucid is positioning to capture once contracts are signed.

Financial Reality Check and the Medicare Catalyst

Lucid ended Q2 with $33.4 million in cash, and the quarterly burn held at approximately $11.3 million. The balance sheet is adequate for another two-plus quarters without any revenue acceleration, but the runway is not unlimited. The company continues to rely on conservative ASC 606 revenue recognition — revenue is booked only when claims are collected — which keeps recognized revenue far below billable volume. That discipline is appropriate given the reimbursement uncertainty, and it creates meaningful upside leverage when Medicare coverage flips.

While await Medicare, management is encouraged by signs the federal LCD backlog is loosening. In his prepared remarks, Aklog noted: “there does seem to be a sign that backlog may be loosening” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-08-13, pointing to several long-awaited LCDs posted in recent weeks. The company also expects its cost-effectiveness model — developed with the lead author of the ACG guidelines — to be completed this summer, with preliminary results showing EsoGuard is cost-effective versus current care. That economic evidence is aimed squarely at commercial payers.

The market has clearly priced in a binary outcome: LUCD shares are down more than 90% from their 2021 peak and have weakened another 16% over the past 90 days, trading near $0.94. But the Concert policy is the first concrete, third-party validation of the clinical — and now commercial — case for EsoGuard outside of Medicare. As management pointed out, it sets a precedent for other LBMs. The company’s free cash flow is still deeply negative, but the mix shift toward contracted and government revenue, coupled with the potential one-year look-back on Medicare claims, argues that the path to positive cash flow is now more visible than it has been in years.

In a sector where many small diagnostics companies wait passively for payer decisions, Lucid’s proactive commercial execution — locking down an LBM, aligning health-system EHR workflows, and building HEOR infrastructure — stands out. The next few quarters will determine whether this foundation translates into the transformative Medicare revenue.

Concert concluded that EsoGuard is medically necessary for patients meeting established screening criteria and that the evidence definitively demonstrates improved health outcomes.